Effects of Late Dinner Against Early Dinner on Weight Loss Healthy Obese Women

Effects of Late Dinner Against Early Dinner on Weight Loss Healthy Obese Women in a Weight-loss Program: a Randomized Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03129841

Enrollment

Registered

2017-04-26

Start date

2017-06-01

Completion date

2017-11-18

Last updated

2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Overweight

Keywords

weight loss, dietary pattern, late dinner, early dinner

Brief summary

The aim of the present study is to test whether late eating dinner could affect the amount of weight loss in healthy obese women in a weight-loss program.

Interventions

BEHAVIORALEarly dinner+Diet

Subjects are asked to eat dinner meals between 7:00- 7:30 PM in the ED group, while they are on a multidisciplinary weight loss plan for 12 weeks.

BEHAVIORALLate dinner+Diet

Subjects are asked to eat their dinner meal between 10:30-11:00PM, while they are on a multidisciplinary weight loss plan for 12 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Must have Body mass index (BMI) between 27-35 kg/ m². * Must be able to have moderate exercise. * Must be interested to have weight loss.

Exclusion criteria

* Participating in a research project involving weight loss or physical activity in the previous six months. * Pregnancy or lactation during the previous 6 months, or planned pregnancy in the next six months. * Taking medication that could affect metabolism or change body weight. * Report heart problems, chest pain, and cancer within the last five years. * Smoking * Menopause * Diagnosis of any chronic disease such as fatty liver, cancer, chemo/radio therapy, heart disease, immune compromised conditions, abnormal thyroid hormone level.

Design outcomes

Primary

Measure	Time frame	Description
weight loss	12 Weeks	kg

Secondary

Measure	Time frame	Description
fasting plasma glucose	12 Weeks	mmol/L
insulin level	12 Weeks	mU/l
insulin resistance (HOMA-IR)	12 Weeks	Score
waist circumference	12 Weeks	cm
lipid profiles	12 Weeks	mmol/l
Liver Enzyme (SGOT, SGPT)	12 Weeks	U/l
glycosylated hemoglobin (HbA1c)	12 Weeks	percentage (%)

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026